|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Group** | **n=** | **Cell therapy** | **Rapamycin and antibody treatment** | **Sensitization to Phl p 5 and Bet v 1**  | ***In-vivo* endpoints** |
| Phl p 5+ B cells | 29 | 1 x 107 isolated CD19+ B cells  | Rapamycin (0.1 mg/mouse, d-1/0/2) + anti-CD40L mAB (1 mg/mouse, d0) | + | WBP w16 (n=13)SPT w17 (n=7)WBP w39 (n=6) |
| No cell transfer | 19 | - | - | + | WBP w16 (n=11)SPT w17 (n=2)WBP w39 (n=6) |
| No cell transfer + IS | 3 | - | Rapamycin (0.1 mg/mouse, d-1/0/2) + anti-CD40L mAB (1 mg/mouse, d2) | + | - |
| Phl p 5+ BM | 6 | 2 x 107 unseparated BMC | Rapamycin (0.1 mg/mouse, d-1/0/2) + CTLA4Ig (0,5 mg/mouse, d2) | + | - |
| Phl p 5+ B +anti-CTLA4 | 5 | 1 x 107 isolated CD19+ B cells | Rapamycin (0.1 mg/mouse, d-1/0/2) + anti-CD40L mAB (1 mg/mouse, d2) + anti-CTLA mAB (1 mg/mouse, d21, 0.5 mg, d23, 25 and 27) | + | SPT w17 (n=5) |
| Phl p 5+ B +anti-PD-1 | 4 | 1 x 107 isolated CD19+ B cells | Rapamycin (0.1 mg/mouse, d-1/0/2) + anti-CD40L mAB (1 mg/mouse, d2) + anti-PD1 mAB (1 mg/mouse, d21, 0.5 mg, d23, 25 and 27) | + | SPT w17 (n=5) |
| Phl p 5+ CD4+ T cells | 3 | 1 x 107 isolated CD4+ T cells | Rapamycin (0.1 mg/mouse, d-1/0/2) + anti-CD40L mAB (1 mg/mouse, d2) | + | - |
| Phl p 5+ CD8+ T cells | 3 | 1 x 107 isolated CD8+ T cells | Rapamycin (0.1 mg/mouse, d-1/0/2) + anti-CD40L mAB (1 mg/mouse, d2) | + | - |
| Phl p 5+ T cells | 5 | 5 x 106 isolated CD4+ T cells +5 x 106 isolated CD8+ T cells | Rapamycin (0.1 mg/mouse, d-1/0/2) + anti-CD40L mAB (1 mg/mouse, d2) | + | - |
| Phl p 5+ GM-CSF DC | 5 | 1 x 107 GM-CSF stimulated DCs | Rapamycin (0.1 mg/mouse, d-1/0/2) + anti-CD40L mAB (1 mg/mouse, d2) | + | - |
| Phl p 5+ Ftlt3 DC | 6 | 1 x 107 Flt3L stimulated DCs | Rapamycin (0.1 mg/mouse, d-1/0/2) + anti-CD40L mAB (1 mg/mouse, d2) | + | - |
| Phl p 5+ B +CTLA4Ig | 3 | 1 x 107 isolated CD19+ B cells  | Rapamycin (0.1 mg/mouse, d-1/0/2) + CTLA4Ig mAB (0.5 mg/mouse, d2) | + | - |